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showed comparable effects on MS relapse rate and EDSS 
change, with IM IFNβ-1a and GA being more tolerable with 
respect to injection site reactions and flu-like symptoms, re-
spectively.  Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 The efficacy and tolerability of injectable interferon-β 
(IFNβ) and glatiramer acetate (GA) as first-line disease-
modifying therapies (DMTs) for the treatment of multi-
ple sclerosis (MS) have been validated in pivotal phase 3 
trials  [1–5] . Across several clinical studies, IFNβ and GA 
reduced the average patient MS relapse rate by approxi-
mately one third  [1–4] and decreased magnetic resonance 
imaging (MRI) T2-weighted brain lesion volume and the 
number of gadolinium-enhancing brain lesions com-
pared with placebo  [5, 6] . However, the comparative ef-
ficacy of these immunomodulatory therapies remained 
uncertain, since it cannot be derived from past trial re-
sults because of differences in study methodology, out-
come criteria, and patient populations among trials.
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 Abstract 
 Background: There is a scarcity of reports comparing effi-
cacy and tolerability of the multiple sclerosis (MS) disease-
modifying therapies [DMTs; intramuscular interferon-β1a 
(IM IFNβ-1a), subcutaneous (SC) IFNβ-1a, SC IFNβ-1b, SC 
glatiramer acetate (GA)] in a real-world setting.  Methods: 
 This multicenter, non-interventional, retrospective cohort 
study analyzed data from 546 patients with clinically isolated 
or relapsing-remitting MS constantly treated with one DMT 
for 2 years. Annualized relapse rate (ARR), Expanded Disabil-
ity Status Scale (EDSS) scores, and DMT tolerability were as-
sessed.  Results: Demographic data were comparable across 
DMTs. There were no significant differences between DMT 
groups in ARR during study year 1 (p = 0.277) or study year 2 
(p = 0.670), or in EDSS change between years 1 and 2 (p = 
0.624). Adverse events were frequent (39–56%) in all groups. 
Flu-like symptoms were less frequent with GA treatment 
(2.3% vs. IM IFNβ-1a, 46.7%; SC IFNβ-1a, 39.8%; SC IFNβ-1b, 
25.8%; p < 0.05). Injection site reactions were less often re-
ported with IM IFNβ-1a (10.5% vs. SC IFNβ-1a, 33.9%; SC 
IFNβ-1b, 38.3%; GA, 26.1%; p < 0.05).  Conclusions: All DMTs 
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 Previous DMT comparative studies have typically 
evaluated only 2 of the four commercially available inject-
able therapies  [7–10] . Two large, pharmaceutical indus-
try-sponsored head-to-head trials showed that self-in-
jectable subcutaneous (SC) IFNβ was not superior to GA 
with regard to clinical efficacy outcomes over 2 years  [7, 
8] . There have also been 2 reported head-to-head trials 
that showed superior efficacy for SC IFNβ compared with 
intramuscular (IM) IFNβ in lengthening the time to the 
first clinical relapse on study  [9, 10] . However, study pop-
ulations in phase 2 and 3 clinical trials may not represent 
the general population in which the studied drugs will be 
used after approval, and it is therefore well recognized 
that clinical trial results may only be partially reproduc-
ible in general clinical practice.
 Several open-label, postmarketing, observational stud-
ies have reported similar efficacy for the three different 
IFNβ preparations  [11–19] , but only a few have com-
pared these DMTs and GA  [20, 21] . There is only one re-
port in the literature comparing the effects of all four dif-
ferent immunomodulatory therapies on MS disease pro-
gression in patients with relapsing-remitting MS (RRMS); 
however, the study groups were quite imbalanced, and 
the reported differences in hazard ratios between the 
DMTs were attributed to selection bias  [22] . So far, mul-
ticenter clinical data comparing the use of all four inject-
able DMTs in patients with clinically isolated syndrome 
(CIS) or RRMS have not previously been reported. We 
present the results of a retrospective study comparing ef-
ficacy, safety, and tolerability of the three IFNβ prepara-
tions and GA in patients with CIS or RRMS in a real-
world setting.
 Methods 
 Patients 
 The Swiss Analysis of Multiple Sclerosis (SAME) study was a 
multicenter, non-interventional, retrospective cohort study that 
included patients constantly treated for at least 2 years with either 
one of the IFNβ or GA at 30 centers in Switzerland. The inclusion 
criteria were age between 18 and 65 years at first visit, a diagnosis 
of either CIS or RRMS according to the 2005 revised McDonald 
criteria  [23] , and treatment with the same DMT for the last 2 years. 
Availability of patient demographic information, medical history, 
and results of neurological examinations were required for inclu-
sion in the study. All patients who met these criteria from June to 
October 2010 were included. Eligible patients had received con-
tinuous treatment with one of four first-line DMTs (IM IFNβ-1a 
30 μg, Avonex ® ; SC IFNβ-1a 22/44 μg, Rebif ® ; SC IFNβ-1b 250 
μg, Betaferon ® , or GA 20 mg, Copaxone ® ) at standard doses for 
at least 2 years (i.e. the study period). Use of any MS treatment for 
any duration was allowed prior to the study period. Study exclu-
sion criteria were DMT treatment <2 years, interruption in DMT 
therapy during the study period, therapy that did not include a 
first-line DMT, or the occurrence of an MS relapse during the 4 
weeks immediately prior to enrollment in SAME. All patients pro-
vided informed consent, and the study was approved by each 
study site’s institutional review board or clinical research ethics 
committee.
 Study Design 
 The SAME study was a multicenter, non-interventional, retro-
spective cohort study that analyzed data from patients treated at 
one of 30 MS centers in Switzerland with an IFNβ or GA for at least 
2 years. The study period was defined as 24 months of continuous 
use of the same DMT and was divided into the two time intervals 
of the first 12 months (year 1) and the second 12 months (year 2) 
of the study period ( fig. 1 ).
 For each patient, participating investigators completed a case 
report form that requested information on patient demographic 
and clinical data, including date of birth, gender, date of CIS or 
RRMS diagnosis, preparation and dose of the DMT, first treat-
ment after MS diagnosis prior to the start of the SAME study pe-
riod (i.e. ‘initial therapy’), number of relapses, and Expanded Dis-
ability Status Scale (EDSS) scores. MRI scans were performed ac-
cording to clinical need and in only a limited number of patients 
(27%, data not shown). Participating study sites entered data us-
ing a secure, web-based tool created for the study that ensured the 
quality of the data collection and also allowed for consolidated 
monitoring.
 The primary study end point was the annualized relapse rate 
for years 1 and 2 (categorized as 0, 1, 2, or  ≥ 3). A relapse was de-
fined, according to widely accepted international diagnostic and 
therapeutic guidelines  [23] , as newly developed neurological 
symptoms or reactivation of preexisting neurological deficits for a 
minimum of 24 h in the absence of an increase in body tempera-
ture or infections, or as symptoms occurring at least 30 days after 
the preceding episode. The secondary end point was change in 
patient EDSS score from year 1 to year 2. In addition, treatment-
associated adverse events (AEs) during SAME study years 1 and 2 
were collected in all patients [categorized into flu-like symptoms, 
injection site reactions (redness ,  inflammation ,  necrosis ,  and li-
poatrophy), and other].
Data analysis End Start
Study months –24 –12 0
DMT therapy First year Second year
 Fig. 1. SAME study timeline. 
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 Statistical Analyses 
 The planned analysis compared the number of relapses, EDSS 
score, change in EDSS score, and frequency of AEs between treat-
ment groups. In addition, patients who had switched to DMT 
before the study (the ‘switch’ group) were compared with those 
for whom DMT was the first treatment (the ‘no-switch’ group). 
Because of the non-normal distribution of the outcomes, com-
parisons used nonparametric tests (U tests, Kruskal-Wallis one-
way analysis of variance, and χ 2 tests, as appropriate). Bonferroni 
post hoc tests were conducted for comparisons that showed over-
all significant differences. Results were considered significant at 
p < 0.05.
 Results 
 A total of 546 subjects were enrolled in SAME. Patient 
demographic were similar across all four treatment 
groups ( table  1 ). The overall mean age at enrollment
(± standard deviation) was 44 ± 10.5 years, and the ma-
jority of patients (70%) were women. Ninety percent of 
patients presented with RRMS. Disease duration was 
largely comparable across treatment groups for CIS pa-
tients, though RRMS patients treated with SC IFNβ-1b 
had a longer disease duration than patients treated with 
IM IFNβ-1a (p < 0.05, post hoc test;  table 1 ). There were 
no significant differences between groups in relapse rate 
( fig. 2 ) or EDSS score during years 1 or 2 ( fig. 3 and  ta-
ble 1 ). In addition, change in EDSS score from year 1 to 
year 2 did not differ significantly between treatment 
groups (p = 0.624, Kruskal-Wallis one-way analysis of 
variance).
 A total of 88 patients (22 on IM IFNβ-1a, 16 on SC 
IFNβ-1a, 8 on SC IFNβ-1b, and 42 on GA) had used dif-
ferent DMTs prior to SAME. When patients receiving a 
DMT as their first drug (458 patients) and those receiving 
a DMT as their second drug (88 patients) were compared, 
the 2 groups did not differ in age, gender, or proportion 
of patients with RRMS or CIS ( table 1 ). Patients who had 
switched to a DMT had a longer disease duration and 
higher EDSS scores both during year 1 and 2 than those 
who had originally received a DMT. The EDSS change 
between year 1 and 2 was, however, comparable between 
groups (p = 0.472, Mann-Whitney U test).
Table 1.  Patient demographic and clinical characteristics
All DMTs  DMT p
value
Switch vs. no switch p
value
 IM IFNβ-1a SC IFNβ-1a SC IFNβ-1b GA DMT as
first therapy
switch
to DMT
Patients 546 (100) 105 (19) 186 (35) 167 (30) 88 (16) – 458 (84) 88 (16) –
Males 164 (30) 24 (23) 61 (33) 52 (31) 27 (31) 0.339a 139 (30) 25 (28) 0.716a
Age, years 44.0 ± 10.5 43.6 ± 11.5 43.6 ± 10.3 45.0 ± 10.4 43.4 ± 9.9 0.530b 43.9 ± 10.5 44.3 ± 10.4 0.772b
Diagnosis
RRMS 492 (90) 92 (88) 175 (94) 145 (87) 80 (91) 0.106a 410 (89) 82 (79) 0.292a
CIS 54 (10) 13 (12) 11 (6) 22 (13) 8 (9) 48 (11) 6 (7)
Median disease duration, years 
RRMS 7.7 (4.8 – 12.8) 6.0 (3.7 – 11.3)c 7.5 (5.7 – 11.7) 9.5 (4.8 – 15.2)c 7.6 (4.3 – 12.8) 0.007d 7.3 (4.4 – 11.8) 11.7 (6.9 – 15.5) <0.001e
CIS 4.3 (3.0 – 7.4) 4.5 (3.0 – 6.8) 5.5 (3.7 – 7.3) 3.4 (2.8 – 4.8) 8.1 (3.4 – 13.0) 0.244d 4.1 (2.9 – 6.8) 6.7 (3.1 – 11.7) 0.459e
Number of relapses
Year 1
0 438 (80) 83 (79) 142 (76) 141 (84) 72 (82) 0.277a 371 (81) 67 (76) 0.294a
≥1f 108 (20) 22 (21) 44 (24) 26 (16) 16 (18) 87 (19) 21 (24)
Year 2
0 413 (76) 79 (75) 136 (73) 129 (77) 69 (78) 0.670a 355 (77) 58 (66) 0.066a
1 105 (19) 21 (20) 38 (20) 33 (20) 13 (15) 81 (18) 24 (27)
≥2g 28 (5) 5 (5) 12 (7) 5 (3) 6 (7) 22 (5) 6 (7)
Median EDSS
Year 1 2 (1.5 – 3.0) 2 (1.5 – 3.0) 2.25 (1.5 – 3.5) 2 (1.5 – 3.5) 2.5 (1.5 – 3.0) 0.196d 2 (1.5 – 3) 2.5 (1.5 – 3.5) 0.019e
Year 2 2 (1.5 – 3.5) 2 (1.0 – 3.0) 2 (1.5 – 3.5) 2 (1.5 – 4.0) 2.5 (1.3 – 3.0) 0.167d 2 (1.5 – 3.5) 2.5 (2 – 4) 0.009e
 Values for age are expressed as mean ± SD. Figures in parentheses indicate percentages or interquartile range. a χ2 test. b Analysis of variance. c Post-hoc 
comparison, adjusted p < 0.05 for pairwise comparison. d Kruskal-Wallis one-way analysis of variance. e Mann-Whitney U test. f Only 8 patients had two or 
more relapses during year 1. g Only 3 patients had three or more relapses during year 2.
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Table 2.  AEs during 2-year DMT in MS
AEs  DMT p
valuea IM IFNβ-1a SC IFNβ-1a SC IFNβ-1b GA all DMTs
Any AEs 59 (56.2) 102 (54.8) 89 (53.3) 34 (38.6) 284 (52.0) 0.052
Flu-like symptoms 49 (46.7) 74 (39.8) 43 (25.8) 2 (2.3) 168 (30.8) <0.001
Injection-site reactionsb 11 (10.5) 63 (33.9) 64 (38.3) 23 (26.1) 161 (29.5) <0.001
Redness 10 (9.5) 56 (30.1) 59 (35.3) 16 (18.2) 141 (25.8)
Inflammation 4 (3.8) 19 (10.2) 19 (11.4) 3 (3.4) 45 (8.2)
Necrosis 0 4 (2.2) 8 (4.8) 1 (1.1) 13 (2.4)
Lipoatrophy 0 10 (5.4) 11 (6.6) 7 (8.0) 28 (5.1)
Other 12 (11.4) 18 (9.7) 10 (6.0) 13 (14.8) 53 (9.7) 0.135
 a Treatment differences in AEs were analyzed using χ2 tests, with significance accepted when p < 0.05. b Individual patients recorded 
one or more types of injection site reactions. Percentages are given in parentheses.
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 Overall, patient reports of treatment-related AEs did 
not differ significantly (p = 0.052) between treatment 
groups, although some group differences in specific AEs 
were evident ( table 2 ). The predominant AEs were flu-
like symptoms and local injection site reactions. Reports 
of flu-like symptoms were significantly less frequent 
with GA compared to all other DMTs and SC IFNβ-1b 
compared to IM IFNβ-1a and SC IFNβ-1a (adjusted p < 
0.05 for all post hoc comparisons). On the other hand, 
patients on IM IFNβ-1a experienced significantly fewer 
injection site reactions (p < 0.001) than patients on the 
other three DMTs, with redness and inflammation be-
ing the most commonly reported injection site reac-
tions.
 Discussion 
 This multicenter, retrospective, observational study
in a selected real-world MS population of nearly 550
patients demonstrated that the four first-line DMTs for 
the treatment of MS had a similar impact on annualized 
relapse rate and disability progression (as indicated
by change in EDSS score) during the 2-year study. There 
were no major differences in AEs between patients receiv-
ing the different DMTs, although the prevalence of injec-
tion site reactions and flu-like symptoms seemed to be 
lower with IM IFNβ-1a and GA, respectively. To our 
knowledge, this is the first study that simultaneously 
compared the efficacy and side effects of these four first-
line DMTs in a large cohort of patients affected by RRMS 
and CIS in a multicenter real-world setting. Our study 
population of 546 patients from 30 Swiss centers repre-
sents approximately 10% of the estimated Swiss MS pop-
ulation. The current study evaluated an MS patient co-
hort during a 2-year period of uninterrupted first-line MS 
therapy. Given that the majority (87%) of patients in the 
SAME study had been on the same DMT for many years, 
we suggest that these patients represent a selected, stable, 
real-world MS patient population. In addition, we con-
ducted a separate analysis that stratified the group into 
patients receiving the DMT as first- or second-line treat-
ment and showed that the latter group, as expected, was 
more severely affected in terms of disability. However, 
relapse rate and disability progression over 2 years did not 
differ between the 2 groups. All of the AEs reported by 
patients were expected, and they occurred at similar fre-
quencies as in previous reports  [24] .
 These results are in line with other short- and long-
term real-world postmarketing studies  [11–21] . Never-
theless, 2 previous head-to-head trials, EVIDENCE  [9] 
and INCOMIN  [10] , showed superior efficacy for SC 
IFNβ compared with IM IFNβ in terms of time to the first 
clinical MS relapse on study. However, differences be-
tween treatment groups in patient baseline characteris-
tics, variation in MS therapies prior to study initiation, 
absence of a placebo comparator group, regression to the 
mean, and possible selection bias may limit the utility of 
those data.
 The study has several limitations that should be tak-
en into account when interpreting its results. The first 
and most important limitation is represented by the
retrospective nonrandomized study design. In general, 
randomized studies have a better research design, since 
possible biases cannot be fully overcome by statistical 
methods in open-label, non-randomized studies  [25] . 
However, it is not always feasible to conduct randomized 
trials, and alternative study designs will inevitably need to 
be utilized. Benson and Hartz  [26] reported that the esti-
mates of treatment effects from observational studies and 
randomized controlled trials are similar. The value of ob-
servational studies should therefore not be underestimat-
ed since phase 4 studies and retrospective chart reviews 
can also reveal important differences among drugs in the 
same class that were not detected in controlled phase 2 or 
3 clinical trials  [17] . In addition, in Switzerland all DMTs 
are approved first-line treatments for MS patients. The 
official administrative recommendations do not differ 
among DMTs, and there are no guidelines that preferen-
tially recommend one specific DMT for these patients. 
Therefore, we can tentatively assume that all DMTs in our 
study were prescribed with the same a priori probability 
in MS patients.
 Second, patients on stable DMT treatment for at least 
2 years in the SAME study most likely represent long-
term responders to DMTs or patients with low disease 
activity; they may differ from the general population of 
MS patients. As a consequence, we cannot generalize our 
results to the entire MS population. Finally, the absence 
of a systematic MRI follow-up precludes from identifying 
differences in subclinical disease activity, which is more 
sensitive than clinical parameters only.
 To conclude, in a real-world setting in a selected MS 
patient population the four injectable DMTs showed 
more similarities than differences in the efficacy and safe-
ty of the treatment of MS during a 2-year study period.
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